Apogee Therapeutics, Inc. Quarterly Additional Paid in Capital in USD from Q3 2023 to Q2 2024

Taxonomy & unit
us-gaap: USD
Description
Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.
Summary
Apogee Therapeutics, Inc. quarterly Additional Paid in Capital history and growth rate from Q3 2023 to Q2 2024.
  • Apogee Therapeutics, Inc. Additional Paid in Capital for the quarter ending June 30, 2024 was $964M.
Additional Paid in Capital, Quarterly (USD)
Period Value YoY Chg Change % Date Report Filed
Q2 2024 $964M Jun 30, 2024 10-Q 2024-08-12
Q1 2024 $958M Mar 31, 2024 10-Q 2024-05-13
Q4 2023 $503M Dec 31, 2023 10-Q 2024-08-12
Q3 2023 $501M Sep 30, 2023 10-Q 2023-11-13
* An asterisk sign (*) next to the value indicates that the value is likely invalid.